Marelim

Mycophenolic Acid, the active ingredient in Marelim, is an immunosuppressant (antimetabolite) presented as an oral formulation for oral use. It is employed to prevent acute organ‑rejection episodes and to manage selected autoimmune disorders, particularly in patients who have undergone kidney, heart, or liver transplantation.

GNH USA supplies Marelim as a licensed, GDP‑compliant international pharmaceutical product to hospitals, transplant centres and pharmacies worldwide. The company adheres to EU quality standards and provides regulatory documentation to support safe import and distribution. Customer support is available for technical queries and batch traceability.

Marelim, an immunosuppressant targeting lymphocyte proliferation, is indicated for the following clinical situations: - Renal transplantation: helps prevent acute graft rejection by suppressing T‑cell activation. - Cardiac transplantation: reduces incidence of early rejection episodes through inhibition of lymphocyte proliferation. - Hepatic transplantation: supports graft survival by limiting immune‑mediated damage. - Lupus nephritis: contributes to disease control by decreasing auto‑antibody production and renal inflammation.

Mycophenolic Acid may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Gastrointestinal upset: nausea, vomiting, diarrhea, or abdominal pain. - Infections: increased susceptibility to bacterial, viral, or fungal infections. - Hematologic changes: leukopenia, anemia, or thrombocytopenia. - Headache: mild to moderate intensity.

Serious or Rare Side Effects: - Severe infection: opportunistic infections such as Pneumocystis jirovecii pneumonia. - Bone marrow suppression: profound pancytopenia requiring medical intervention. - Gastrointestinal perforation: rare cases of intestinal ulceration or perforation. - Hepatotoxicity: elevated liver enzymes or hepatitis.

When prescribing Marelim, clinicians should consider several precautionary measures to minimize risk and ensure safe use. - Pregnancy risk: classified as Category D; use only if benefits outweigh potential fetal harm. - Renal function: adjust monitoring in patients with impaired renal clearance. - Hepatic function: monitor liver enzymes regularly due to potential hepatotoxicity. - Infection monitoring: screen for latent infections and vaccinate before initiation when appropriate. - Drug interactions: review concomitant medications that may increase mycophenolic acid levels. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and direct sunlight.

Marelim can interact with other medicines, altering its plasma concentration or enhancing immunosuppressive effects.

Major Interactions (Avoid): - Cyclosporine or tacrolimus: combined use may increase mycophenolic acid exposure and risk of toxicity. - Antiviral agents (e.g., valganciclovir): may raise plasma levels, requiring dose adjustment.

Moderate Interactions (Monitor Closely): - Antacids containing aluminum or magnesium: can reduce absorption; separate dosing by at least 2 hours. - Rifampin or other enzyme inducers: may lower mycophenolic acid concentrations, reducing efficacy. - Warfarin: may enhance anticoagulant effect; monitor INR closely.